Polycystic Ovarian Syndrome - Pipeline Review, H2 2015

Published: Jul, 2015 | Pages: 54 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Polycystic Ovarian Syndrome - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Polycystic Ovarian Syndrome - Pipeline Review, H2 2015', provides an overview of the Polycystic Ovarian Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Polycystic Ovarian Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Polycystic Ovarian Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Polycystic Ovarian Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Polycystic Ovarian Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Polycystic Ovarian Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Polycystic Ovarian Syndrome Overview 7
Therapeutics Development 8
Pipeline Products for Polycystic Ovarian Syndrome - Overview 8
Pipeline Products for Polycystic Ovarian Syndrome - Comparative Analysis 9
Polycystic Ovarian Syndrome - Therapeutics under Development by Companies 10
Polycystic Ovarian Syndrome - Therapeutics under Investigation by Universities/Institutes 11
Polycystic Ovarian Syndrome - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Polycystic Ovarian Syndrome - Products under Development by Companies 15
Polycystic Ovarian Syndrome - Products under Investigation by Universities/Institutes 16
Polycystic Ovarian Syndrome - Companies Involved in Therapeutics Development 17
Addex Therapeutics Ltd 17
AstraZeneca Plc 18
BIOCAD 19
Crinetics Pharmaceuticals, Inc. 20
EffRx Pharmaceuticals S.A. 21
Euroscreen S.A. 22
Merck KGaA 23
Vicore Pharma AB 24
Polycystic Ovarian Syndrome - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
AZD-4901 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
C-21 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
choriogonadotropin alfa - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ESN-364 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
follitropin alfa - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
JDSCR-004 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
KDT-501 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
metformin hydrochloride - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Polycystic Ovarian Syndrome - Recent Pipeline Updates 46
Polycystic Ovarian Syndrome - Dormant Projects 48
Polycystic Ovarian Syndrome - Product Development Milestones 49
Featured News & Press Releases 49
Apr 21, 2015: Euroscreen starts in parallel two Phase 2 clinical trials with ESN364 in UF and PCOS patients 49
Dec 08, 2014: Euroscreen Announces Positive Completion of Phase I Trial of ESN364 49
Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting 50
Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome 50
Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN364 51
Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Paediatric Populations 51
Feb 05, 2013: Euroscreen to present ESN364 drug candidate at the 11th International Symposium on GnRH 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54

List of Tables

Number of Products under Development for Polycystic Ovarian Syndrome, H2 2015 8
Number of Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Late Stage Development, H2 2015 12
Comparative Analysis by Clinical Stage Development, H2 2015 13
Comparative Analysis by Early Stage Development, H2 2015 14
Products under Development by Companies, H2 2015 15
Products under Investigation by Universities/Institutes, H2 2015 16
Polycystic Ovarian Syndrome - Pipeline by Addex Therapeutics Ltd, H2 2015 17
Polycystic Ovarian Syndrome - Pipeline by AstraZeneca Plc, H2 2015 18
Polycystic Ovarian Syndrome - Pipeline by BIOCAD, H2 2015 19
Polycystic Ovarian Syndrome - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2015 20
Polycystic Ovarian Syndrome - Pipeline by EffRx Pharmaceuticals S.A., H2 2015 21
Polycystic Ovarian Syndrome - Pipeline by Euroscreen S.A., H2 2015 22
Polycystic Ovarian Syndrome - Pipeline by Merck KGaA, H2 2015 23
Polycystic Ovarian Syndrome - Pipeline by Vicore Pharma AB, H2 2015 24
Assessment by Monotherapy Products, H2 2015 25
Number of Products by Stage and Target, H2 2015 27
Number of Products by Stage and Mechanism of Action, H2 2015 29
Number of Products by Stage and Route of Administration, H2 2015 31
Number of Products by Stage and Molecule Type, H2 2015 33
Polycystic Ovarian Syndrome Therapeutics - Recent Pipeline Updates, H2 2015 46
Polycystic Ovarian Syndrome - Dormant Projects, H2 2015 48